Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine - Interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW

This article has no abstract
Epistemonikos ID: bc522b8a77f9e9388fb32d155ebb7fc725faa04c
First added on: Feb 05, 2025